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ABSTRACT 
In-stent restenosis still occurs in coronary arteries implanted with drug-eluting stents, 
with the maximum thickness observed at the vascular site of maximum inter-strut angle. 
This phenomenon may be related to the specific spatiotemporal drug uptake in the arterial 
wall. In this work local delivery of a hydrophobic drug from a drug-eluting stent 
implanted in a coronary artery is investigated using a mathematical model that couples 
drug diffusion and reversible binding in the arterial wall. The model is solved by the 
finite volume method with varied stent-coating and vascular diffusivities for (i) drug 
loading at concentrations less than or equal to the solubility, and (ii) high drug loading at 
concentrations greater than the solubility. Drug release profiles in the coating are 
observed to depend not only on the coating diffusivity but also on the properties of the 
surrounding arterial wall. Distinguished dependence on the vascular diffusivity and 
coating diffusivity of the spatially-averaged drug levels in the wall at quasi-steady state 
are discussed. Anisotropic drug diffusivities result in similar average drug levels in the 
arterial wall but very different spatial distributions. Higher circumferential vascular 
diffusivity results in more uniform drug loading in the upper layers and is potentially 
beneficial in reducing in-stent restenosis. An analytical expression is derived for 
determining whether higher free-drug concentration than that of bound-drug can occur in 
the arterial wall.  
Keywords: drug-eluting stents, hydrophobic drug, mathematical modeling, intravascular 
delivery, restenosis, reversible binding  
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CHAPTER 1 
INTRODUCTION 
Drug-eluting stents have shown great improvement in reducing In-Stent Restenosis after 
angioplasty procedures compared with bare metal stents [1-4]. The device enables a 
prolonged local delivery of active drugs, such as sirolimus or paclitaxel, which are 
embedded in and released from the polymeric stent-coating and can interrupt certain 
stages in in-stent restenosis formation [5-7]. Great efforts have been carried out towards 
stent design [8], in vitro drug release from polymeric stent-coating [9-13] (with various 
configurations including but not limited to drug type and loading, polymer type and 
molecular weight, coating thickness), drug physiochemical and physiological properties 
[7, 14-16], in vivo examination of drug delivery and arterial drug uptake [15, 17-21], and 
in-stent restenosis formation [22-26].  Nevertheless, the in vivo study of drug-eluting 
stents is limited by factors such as huge time requirement and the complexity and 
difficulty in measurement and quantification.    
Modeling and simulation offers an alternative approach for drug-eluting stents 
study and can improve our understanding of in vivo drug-eluting stent functions. Drug 
release from coating and drug-vascular tissue interactions were studied in one-
dimensional models [27-29]. Analytical solution for drug diffusion in one-dimensional 
multi-layer wall structure was also derived [30]. Convective and diffusive transports of 
drug in the arterial wall were assessed for both hydrophilic and hydrophobic drugs [31, 
32]. Impact of thrombus [33], blood flow [34, 35], stent coating [36], and strut position 
[37] on stent-based drug delivery was investigated by studying a single strut in an axial 
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cross-section of the artery using a coupled computational fluid dynamics and mass 
transfer model. In a radical cross-section model, drug elution from a fully embedded stent 
strut was found to be most effective with a bi-layer gel paved stent [38]. Multiple struts 
models were also developed to study the impact of different strut configurations (half, 
fully, and not-embedded) and diffusivities [39-41] on arterial drug up-take. Mechanics 
and fluid dynamics simulation has also been done to study stent expansion and 
interaction with coronary artery [42]. Wall stress distributions after insertion and 
deployment were compared by simulation for three different stent designs [43].  
It is reported that in-stent restenosis is more likely to happen in stented coronary 
arteries with non-uniformly distributed struts, with the maximum thickness of neointimal 
hyperplasia occurring at the site with maximum inter-strut angle [23]. In order to 
understand this problem from the perspective of arterial drug-uptake, this work 
mathematically models the delivery of a hydrophobic drug from a drug-eluting stent with 
bio-durable polymeric coating into the arterial wall and incorporates drug release kinetics, 
physiological behavior, and stent geometry. The local drug delivery and distribution is 
studied in a detailed manner for implications on reducing in-stent restenosis for drug-
eluting stents. The long-term objective of our research is to develop mathematical models 
for the in vivo release in the arterial wall from drug-eluting stents, which someday can be 
used for optimal stent design in silico instead of implanting sub-optimal stents into 
patients and waiting to observe undesirable outcomes. 
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CHAPTER 2 
MODEL STRATEGY FOR DRUG-ELUTING STENTS 
2.1 Description of an Implanted Stent 
The type of drug-eluting stent studied in this paper has a bio-durable polymeric coating 
that delivers a hydrophobic drug. This is the case for FDA-approved stents such as 
Cypher stent (Cordis, Johnson & Johnson) and Taxus stent (Boston Scientific). The 
cross-sectional view of the coronary artery with an implanted eight-strut stent [31] is 
illustrated in Figure 1a. Square shape of struts is used with strut dimension a having a 
typical value from Cypher Stents [8,24,42]. The struts are assumed to be distributed 
evenly in the lumen with same degree of embedment in the arterial wall.  
Due to symmetry, the model domain can be reduced to a single strut section 
(indicated by dotted lines in Figure 1a.). Considering that the thickness of the arterial wall 
(Lx, ~200µm [28-29,44]) is small compared to the diameter of the lumen (2.5~3.5 mm 
[10,39,40]), the single strut section is accurately modeled as a rectangular arterial wall 
domain, as in Figure 1b. The inter-strut distance (distance between the centers of two 
adjacent struts), Ly, is estimated for an eight-strut stent in a 3 mm coronary artery. The 
transmural and circumferential directions are labeled as the x and y axis, respectively. 
Blood flow has a direction into the paper plane. Parameters defining the spatial 
dimensions are labeled in Figure 1b, with their values summarized in Table 1. The 
coating thickness δ has values in the literature within the range of 10~100 µm [24,39, 40], 
and a value of 50 µm is used [39,40].  Strut embedment in the wall can range from no 
embedment to fully-embedded [39-41], revealing slightly different uniformity in drug 
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distribution and higher amount of drug in the arterial wall with increased degree of 
embedment. In this work the depth of strut embedment into the wall Lp is used with a 
value close to half-embedment.  
 
  
Figure 1. (a) Cross-sectional view of a stented vessel. Dashed lines show a reduced 
domain by symmetry. (b) Extracted rectangular vascular domain with partial 
embedment of a single stent strut. 
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Table 1. Dimensions and Model Parameters 
Dimensions   
strut dimension a 140 µm [8,24,42] 
coating thickness δ 50 µm [39,40] 
strut embedment LP zero ~ total embedment [39-41] 
arterial wall thickness Lx 200 µm [28,29,44] 
inter-strut distance Ly 1000 µm 
Model parameters   
initial binding site level S0 10-5 M [14] 
initial drug level in the coating C0 10-5 M [29] 
drug solubility in the coating Cs 10-5 M 
drug diffusivity in the coating D1 0.01~1 µm2/s [29,39] 
isotropic drug diffusivity in the wall D2 0.1~10 µm2/s[14,15,29,39] 
transmural diffusivity in the wall D2x 0.1~10 µm2/s 
circumferential diffusivity in the wall D2y 1~100 D2x [14, 17] 
resistance at perivascular boundary Rper 5~100 s/µm [29,31] 
association rate constant (binding) ka 104 M-1s-1 [16,28,29] 
dissociation rate constant (unbinding)  kd 0.01 s-1 [16,28,29] 
partition coefficient at the coating-
arterial wall interface 
CWκ  1 
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2.2 Mathematical Model 
The drug delivery proceeds via pure drug diffusion in the polymeric coating (Eq.(1), 
Table 2) followed by combined drug diffusion and reversible binding in the arterial wall 
(Eq.(2), Table 2) [14,28,29,33]. Drug transport by convection within the arterial wall is 
negligible compared with diffusion [35] due to low local Peclet number [21] and is absent 
in most models [33-34, 36]. The three drug diffusivities D1, D2x, and D2y correspond to 
these in the coating and the transmural and circumferential directions in the arterial wall, 
respectively. Drug binding in the wall is approximated as a first-order reversible reaction 
a
d
k
k
C S B⎯⎯→+ ←⎯  characterized by an association (binding) rate constant ka forming bound 
drug (B) and a dissociation (unbinding) rate constant kd [28,29,34]. The amount of 
available binding sites S at each position within the wall is tracked by the difference 
between the initial binding sites level S0 and bound drug level B.  
Table 2.Mathematical Representation of the Model 
Model Equations 
drug in the coating 
2 2
2 21 1
C C CD D
t x y
∂ ∂ ∂= +∂ ∂ ∂  (1) 
free drug in the 
arterial wall 
( )2 22 22 2 0x y a dC C CD D k S B C k Bt x y∂ ∂ ∂= + − − +∂ ∂ ∂  (2) 
bound drug in the 
arterial wall 
( )0a dB k S B C k Bt
∂ = − −∂  (3) 
 
7 
 
Table 2. (cont.) 
Boundary Conditions 
lumen-wall interface, 
lumen-coating interface, 
perivascular boundary 
1 ( )nmn m
nm nm
C
J C
R κ= −  (4) 
coating-strut interface, 
Left/right wall boundary 
0J =  (5) 
coating-wall interface cw wall coatingC Cκ =  (6) 
 wall coatingJ J=  (7) 
Initial Conditions (t = 0) 
In the coating 
0C C=  
0B =  
In the arterial wall 0C =  
0B =    
The boundary conditions are expressed in flux form at each interface in Table 2. 
Eq.(4) describes the flux Jmn at an interface between domains m and n  by a mass transfer 
resistance Rnm and partition coefficient nmκ [31,32], 
[ / ]nm n m equilibriumC Cκ =  (8) 
For example, at lumen-arterial wall interface, the flux is 
1 ( )WLW L
LW WL
C
J C
R κ= −  (9) 
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which is expressed in terms of the lumen drug level CL, the drug level in the arterial 
wallCW, the partition coefficient [ / ]WL W L equilibriumC Cκ =  and the resistance RWL. Similar 
boundary conditions are also used for lumen-coating interface and perivascular boundary.  
At interfaces with the lumen, drug entering the blood are presumed to be washed 
out, and 0LC =  [28,29,31]. Zero drug concentration in the perivascular space, 0PC = , is 
also used [29,31]. For hydrophobic drug like sirolimus and paclitaxel, the partition 
coefficients are very high (κwl >> 1) [14,15,18,32] and drug partitioning into the arterial 
wall is strongly favored. This and a high resistance imposed by the intimal [20,21] can 
greatly damp the drug depletion into the blood and result in a negligible drug flux into the 
lumen.  
Zero flux boundary condition Eq. (5) applies to the other interfaces including the 
coating-strut interface (physical isolation) and right/left wall boundaries (due to 
symmetry). The boundary conditions at the wall-coating interface are described by 
concentration partitioning (zero resistance) (Eq. (6)) and flux matching (Eq. (7)).  
2.3 Dimensional Analysis 
Some insights of the system characteristics can be obtained from dimensional analysis. 
The characteristic lengths of the coating domain and wall domain are the coating 
thickness δ and lengths Lx and Ly/2, respectively. Define 0/C C C= , 0/B B S= , and non-
dimensionalizeEqs. (1)-(3) to obtain Eqs. (10)-(12) in Table 3. 
Three characteristic time scales appear, τ1, τ2, τ3, corresponding to diffusion in the 
coating, transmural diffusion, and the binding reaction. An evaluation of the magnitude 
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of the three groups gives τ1 ~103-105 s, τ2 ~103-105 s, and τ3 ~102 s, which indicate that 
reversible binding is very fast compared to diffusion. 
Table 3. Non-dimensionalized Equations 
2 2
2 2
1( / ) ( / ) ( / )
C C C
t x y
∂ ∂ ∂= +∂ ∂ ∂τ δ δ  (10) 
( )2 22 21 2 3
2
1
( / ) ( / ) (2 / )x y
C C CG G B C G B
t x L y Lτ
∂ ∂ ∂= + − − +∂ ∂ ∂  (11) 
( )2
3 3
1
( / )
GB B C B
t Gτ
∂ = − −∂  (12) 
Characteristic time scales and dimensionless groups 
2
1 1/Dτ δ=  22 2/x xL Dτ =  3 1/ dkτ =  
2
2
21
2
/
/4
x x
y y
L D
G
L D
=  
2
2 0
2
x
a
x
L
G k S
D
=  
2
0
3
2 0
x d
x
L k S
G
D C
=  
The significance of diffusion and reversible binding in the wall are also implied 
by their corresponding dimensionless groups in Eq. (11). Compared with the coefficient 
of transmural diffusion component (which is 1), the reaction components have very large 
coefficients, G2 ~102-104 and G3 ~101-103, which also implies that the binding reactions 
play a very strong role in the spatiotemporal dynamics. The competition between 
association and dissociation reactions is quantified by G2/G3 ~10 in Eq. (12). Larger 
values for this ratio indicate a preference of association over dissociation. 
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The competition between diffusion in the transmural and circumferential 
directions is implied by the dimensionless group G1. With increasing D2y, the group G1 
increases from ~0.1 to ~10, revealing an increasing importance of circumferential 
diffusion in Eq. (11) compared with transmural diffusion. 
2.4 Numerical Simulation 
The mathematical model in Table 2 was simulated using the finite volume method. To 
illustrate, for a cell centered at (x,y) in a mesh with cell size Δx by Δy, Eq. (2) can be 
expressed as 
( )
2 2
, , , ,2 22 2 2 2
2 2 2 2
0
2 2 2 2
( , , )
( , , ) ( , , ) ( , , )
x yx y
x xx y y yx x y yx y x yx y x y x y
x y x yx y x y
x y x ya dx y x y
d C x y t dxdy J y J y J x J x
dt
k S B x y t C x y t dxdy k B x y t dxdy
Δ Δ+ +
Δ ΔΔ Δ Δ Δ− +− − − +
Δ Δ Δ Δ+ + + +
Δ Δ Δ Δ− − − −
= Δ − Δ + Δ − Δ
− − +
∫ ∫
∫ ∫ ∫ ∫
 (13)
Where xJ , yJ  correspond to the fluxes in x,y directions, respectively.  
Applying a forward-difference approximation of the time derivative with a time 
step Δt and mesh size h = Δx = Δy results in 
( )
( )
1
, ,
/ 2, / 2, , / 2 , / 2
, ,,0
1
n n
i j i j n n n n
x i h j x i h j y i j h y i j h
n n n
i j i ji ja d
C C J J J J
t h
k S B C k B
+
− + − +
− = − + −Δ
− − +
 
(14) 
where superscript n is the index for the time level, subscripts i, j are the indices for x and 
y, ±h/2 indicates the position of the boundaries with neighboring mesh cells, and C and B
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are the average of the free and bound drug levels over the mesh cell centered at (i,j) at 
time index n. Flux across boundary of two adjacent mesh cells was calculated by the 
second-order centered difference, i.e. 
, 1,
/ 2,
n n
i j i jn
x i h j
C CJ D
h
−
−
−= −  (15)
The numerical simulations were implemented in Matlab 2008 running on an Intel-
based personal computer. Values of parameters used in the simulation are summarized in 
Table 1. For drug diffusion in the arterial wall, isotropic drug diffusivity (D2) was first 
investigated, followed by an anisotropic diffusivity study. A range of 0.1~10 µm2/s of the 
transmural diffusivity is investigated [14,15,29,39], while the circumferential diffusivity 
can be the same for large drug molecules or one or two orders of magnitude larger for 
small drugs [14,17]. Reported values are chosen for the association (dissociation) rate 
constants ka (kd) [16,28,29], binding site concentrations (S0) [14], as well as the resistance 
at perivascular interface(R) [29,31]. The partition coefficient at coating-wall interface 
was assumed as one.  
Initial conditions for simulation are summarized in Table 2, which indicates 
uniformly dispersed drug in the polymer coating at concentration C0. The binding sites 
are evenly distributed throughout the arterial wall at concentration S0 initially. 
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CHAPTER 3 
SIMULATION RESULTS AND DISCUSSION 
3.1 Low Initial Drug Load in the Coating (C0 ≤ Cs) 
The drug is completely dissolved in the polymer matrix when the loading is equal to or 
less than the solubility, and the drug transport in the coating is purely diffusion controlled 
[45]. Due to the absence of drug aggregates, the dissolved drug concentration in the stent 
coating decreases gradually with the release. 
3.1.1 Release Profile in the Stent Coating 
The release rate decreases significantly with reduced diffusivity in the stent coating, D1, 
when the isotropic diffusivity in the wall D2 remains constant (see Figure 2). Within the 
simulated range, almost all the drug is released in the first 200 hr at a high coating 
diffusivity D1 of 1 µm2/s, while a two-order lower D1 ensures a prolonged release of the 
drug by releasing about 60% within 400 hr. Lower coating diffusivity is associated with 
prolonged drug release, and this is in agreement with previous findings [36,39].  
Moreover, changes in the vascular diffusivity D2 and the presence of binding in 
the wall both affect the drug release process. Increment of an order in the magnitude of 
D2 significantly enhances the release rate as well, compared to the same change in D1. 
Elimination of the binding reactions results in a slightly reduced release rate, explained 
by the fact that with binding a greater concentration gradient is produced in the wall by 
transferring free drug into bound form [29], and thus faster drug transport from the 
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The spatially-averaged free- and bound-drug concentrations in the arterial wall 
approach quasi-steady values that reduce slowly for most (D1, D2) pairs (see Figure 3). 
The time needed to reach quasi-steady states is estimated by the transmural diffusion time 
scale τ2, around which both the free- and bound-drug levels also reach their peaks.  An 
evaluation of the characteristic time constants with the real dimensions (reduced 
transmural distance due to strut embedment) in Figure 1b gives τ2 = 33.6 hour for D2 = 
0.1 µm2/s. This is in agreement with the peak positions for corresponding plots in Figure 
3. Besides, noticeably the quasi-steady spatially-averaged drug concentrations are 
dominated by the diffusivity in the wall, D2, rather than the diffusivity through the stent 
coating, D1. While all three (D1, D2) pairs with the same D2 (0.1 µm2/s) achieved similar 
quasi-steady spatially-averaged drug concentrations, the fourth (D1, D2) pair with an 
order-of-magnitude higher D2 (1 µm2/s) had a much lower quasi-steady drug level (see 
Figure 3). Under quasi-steady conditions, both diffusion and binding achieve a dynamic 
equilibrium throughout the arterial wall, and with the drug dissipation in the arterial wall 
occurring through the perivascular space, the binding kinetics and the diffusivity D2 
provide the tradeoff that specifies the quasi-steady spatially-averaged drug concentrations. 
Higher diffusivity in the wall speeds the transport of free drug through the arterial wall 
and faster dissipation of drug at the interface of wall-perivascular space. 
While the quasi-steady spatially-averaged drug concentrations are similar for the 
same vascular diffusivity D2, the spatially-averaged drug concentrations are higher in 
early times for increased stent coating diffusivity D1 (see Figure 3). The higher D1 results 
in faster initial drug transport through the stent coating into the arterial wall, before 
approaching quasi-steady spatially-averaged drug concentrations. These observations 
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provide guidance in the design of the stent coating to maintain the drug concentrations in 
the arterial wall within the therapeutic window throughout the treatment. 
3.1.3 Anisotropic Diffusivities in the Wall 
The drug diffusivity in the transmural and circumferential directions tend to be 
anisotropic due to the arterial ultra-structure, mainly attributed by the flat shape of the 
smooth muscle cells [14,17]. For small drug molecules, the circumferential diffusivity 
can be orders of magnitude larger than that in the transmural direction, but the anisotropy 
in the diffusivity gradually diminishes with increasing drug molecules [14,17]. Although 
anisotropic diffusivity was accounted in some of the studies [31,40], there has not been a 
full investigation on this property. In this part of the study, diffusivity anisotropy in the 
arterial wall is studies detail for its impact on the drug level and distribution in the wall.  
The spatially-averaged drug concentrations in the arterial wall were enhanced 
with increased circumferential diffusivity, D2y (see Figure 4). With increased D2y, the 
diffusion in the circumferential direction competes over penetration through the arterial 
wall, reduces the penetrated drug concentration close to the perivascular interface and 
corresponding local drug dissipation. Meanwhile, increased vascular diffusivity in the 
circumferential direction more quickly transports drug in the arterial wall away from the 
stent coating, resulting in faster drug release from the stent coating. These two factors 
contribute to the enhanced spatially-averaged bound-drug concentrations at increased D2y. 
In early times the spatially-averaged free-drug concentration is slightly lower at enhanced 
circumferential diffusivity due to the increased availability of binding sites within the 
arterial wall in which drug has diffused. With the anisotropy ratio (ratio of 
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(Figure 5. C-1), whereas a concentration gradient always exists in the transmural 
direction. At very high circumferential diffusivity, the drug concentrations are well 
approximated as only being a function of time and depth in the transmural direction. 
The time evolution of the drug concentrations at positions P1 and P2 (near the left 
and the perivascular boundaries in Figure 1b) are shown in the right column of Figure 5. 
With increasing circumferential diffusivity D2y, the free- and bound-drug concentrations 
at P1 massively increase, and those at P2 decrease. At increased D2y, drug dissipation at 
the perivascular boundary is reduced with the reduced local drug concentrations, resulting 
in the higher spatially-average drug concentrations observed in Figure 4. 
The first appearance of drug at P1 and P2 corresponds to the diffusion time in each 
direction (see right column in Figure 5). For isotropic diffusion in Figure 5A-2, the 
diffusion time in the circumferential direction (~180 hr) is almost 12 times as long as the 
penetration time (~15 hr). The drug distribution is very non-uniform in the 
circumferential direction when transmural penetration is well established, and areas with 
negligible drug concentrations exist far away from the strut (see Figure 5A-1). Similar 
qualitative results have been reported in which drug binding was absent [31]. The lack of 
drug in upper layers far away from the strut in the circumferential direction can be a 
serious factor of restenosis occurrence, as it is known that high drug concentrations in the 
upper layers of wall is more important than penetration in suppressing restenosis [7]. 
Lack of drug in the upper layers of the arterial wall during the early days after 
implantation provides a potential explanation to the clinical observation that the thickest 
restenosis occurs at the largest inter-strut angle area when the struts are unevenly placed 
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[23]. In addition, this provides an alternative factor to the observed asymmetric cross-
sectional neointimal thickness distribution, for which lower wall shear stress was 
considered as an important factor to induce more neointimal growth [25,26]. 
For D2y = 10D2x, the time evolution of the free- and bound-drug concentrations at 
the left and adventitia boundaries in Figure 5B-2 shows comparable diffusion times with 
both positions initially receiving drug at a similar time (~15 hrs). With even higher D2y 
(100D2x), the diffusion time in the circumferential direction is negligible compared to that 
of penetration (see Figs. 5C-1 and 5C-2). In this case, a fast coverage of drug in the upper 
media layers is achieved within ~2 hr, and nearly uniform drug concentrations in the 
circumferential direction are produced. The potential adverse effect of unevenly placed 
struts could be greatly reduced, compared to isotropic diffusion. These simulations 
indicate that drugs with high anisotropy in diffusivity in the arterial wall are preferable 
from the clinical point of view, in terms of achieving higher and more uniform drug level 
in the upper layers of the arterial wall. 
3.2 High Initial Drug Load in the Coating (C0 >>Cs) 
In real applications high drug loadings are used that are very often orders of magnitude 
higher than the solubility in the matrix and most of the drug is dispersed in the polymer 
matrix in aggregated form [9,12].  
While the drug is released from the stent coating, the dynamic equilibrium 
between drug aggregates and dissolved drug ensures a continuous drug supply. When the 
dynamic equilibrium is fast compared to the release, the drug concentration can be 
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assumed as constant at its solubility within the coating. This is similar to the continuum 
pharmacokinetics investigated in some works [31,35].  
Under this circumstance, the spatially-averaged drug concentrations in the arterial 
wall achieve quasi-equilibrium values (as in Figure 6). The quasi-equilibrium can last 
until the average drug concentration in the coating is eventually reduced close to its 
solubility. Shorter times are required to achieve quasi-equilibrium with increased 
circumferential diffusivity, and the quasi-equilibrium drug levels are enhanced. Due to 
the availability of the abundant drug source in the coating, the trend of enhancement is 
more significant here than in Figure 4. 
The drug distribution profiles for isotropic diffusivity indicate that quasi-
equilibrium has not yet fully established in 400 hours due to the slow diffusion in the 
circumferential direction (Figure 7A-1, 2). The low quasi-equilibrium drug levels at sites 
far away from the strut in the circumferential direction again justifies the finding in 
Section 3.1.3 that maximum restenosis thickness at maximum inter-strut angle is related 
to lack of drug in that position.  
Quasi-equilibrium was established quickly when the circumferential diffusivity 
D2y is enhanced (cases B and C in Figure 7.). In plot B-1, the free-drug concentration 
forms a clear gradient centered at the strut even at quasi-equilibrium, indicating a non-
uniform drug level in both circumferential and transmural directions. When D2y is 
increased to 2 orders in magnitude as large as D2x in Figure 7. C-1, the fast 
circumferential diffusion compared with penetration resulted in planar layers containing 
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Although part of the arterial wall has higher free-drug level than that of bound 
drug, the spatially-averaged concentration is still lower for free drug (see Figure 6). 
These simulations show that, while the spatially-averaged concentrations have higher 
bound-drug concentration than that of free drug, as expected from G2/G3 = 10, this does 
not necessarily hold for individual vascular sites. 
The critical condition for the circumstance that free-drug concentration exceeds 
that of bound-drug can be derived. At equilibrium conditions, the rates of association and 
dissociation in Eq. (3) are equal,  
0( )a dk C S B k B− =  (16) 
This equation can be rearranged to solve for the free-binding-site concentration in 
terms of the free-drug concentration,  
( )0 / 1B KCS KC= +  (17) 
where K = ka/kd is the equilibrium binding constant.  
To acquire a higher concentration of free drug than bound drug, or C > B, the 
condition can be combined with Eq. (17) to give 
0 1/C S K> −  (18) 
The highest free-drug concentration in the wall occurs at the coating-wall 
boundary, where /s CWC C κ=  , and the inequality becomes 
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0/ 1/s CWC S Kκ > −  (19) 
When this inequality is satisfied, higher free-drug concentration can occur in the 
region close enough to the strut. The boundary of equal free- and bound-drug 
concentrations is set up by  
0 1/C S K= −  (20) 
which is 0 1/ 9μMC S K= − =  for the simulations in this work. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE WORK  
4.1 Conclusions 
The intravascular drug delivery from a drug-eluting stent and the resulted drug 
distribution in the arterial wall were modeled. Dimensionless groups were defined that 
provided insights into the relative importance of directionally-dependent diffusivities and 
reversible binding on the spatiotemporal distribution of drug in the surrounding arterial 
wall.  
In addition to the drug diffusivities in the coating, the surrounding arterial wall 
itself greatly influences the release from a drug-eluting stent via the drug diffusivity in 
the wall and the presence of binding reactions. The findings imply that in vitro 
measurement of release profiles may not be a close representation of the in vivo release of 
a hydrophobic drug from a drug-eluting stent.  
Moreover, the average drug concentrations in the arterial wall at quasi-steady 
state are greatly determined by the drug diffusivity in the wall rather than the drug 
diffusivity in the stent coating. Anisotropic drug diffusivities in the arterial wall result in 
similar spatially-averaged drug levels but very different spatial distributions, and higher 
free-drug concentration than bound-drug concentration can occur at local sites. The 
critical condition 0/ 1/s CWC S Kκ > −  (Eq. (19)) for the occurrence of the latter phenomena 
was derived. Higher circumferential diffusivity reduces the drug gradient in the 
27 
 
circumferential direction and produces more uniformly loaded drug concentrations, 
which can reduce the thickness of in-stent restenosis after drug-eluting stent treatment.  
Simulation results as presented here provide predictions as to how changes in 
drug properties (such as its directional diffusivity or reversible binding kinetics) influence 
spatial uniformity in the arterial wall and show potential for guiding the design of drug-
eluting stents. 
4.2 Future Work 
The work of this thesis has been focused on bio-durable polymeric stent coatings in 
consideration of the available clinical stents in practice. Meanwhile, biodegradable 
polymers also draws attention in drug-eluting stents coating design due to their favorable 
biocompatibility compared with bio-durable polymer carriers [46-48]. Commonly studied 
biodegradable polymers include poly(lactic-co-glycolic acid) (PLGA) and poly(lactic 
acid)  (PLA) [49-50]. 
A unique feature of biodegradable polymeric coating is the degradation of the 
polymer matrix and resulted change in matrix structure and transport property. The 
degradation process is recognized as a hydrolysis reaction for PLGA and PLA, where the 
polymer chains reacts with water molecules and break into smaller segments [50-52]. 
Drug diffusion within the coating matrix is confined at the beginning due to the very low 
drug diffusivity in the polymer matrix. As degradation goes, micro pore-structures are 
being formed within the coating and drug starts to diffuse out through the micro-tunnels 
built by the pores. The effective drug diffusivity in the coating is a function of the extent 
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of degradation and this leads to a coupled drug diffusion and polymer degradation 
process in the coating.  
Degradation of PLGA/PLA based microspheres together with drug release has 
been extensively studied, but there has not been a unanimous mechanistic model that can 
describe the process precisely [51,53-58]. It has been shown that for PLGA microspheres 
neither bulk scission nor end scission alone can explain the experimental observation but 
a combined mechanism of both [58]. More recently, autocatalytic effect has also been 
proposed to explain accelerated degradation in the interior spheres and models attempt to 
implement this effect have met quite some complexity [56].  
Choosing PLGA (PLA) polymers as our biodegradable coating matrix, the next 
step of our work is to develop a model to describe and predict the coating matrix 
degradation and erosion process, which in turn changes the drug release kinetics in the 
coating. The degradation model can then be incorporated into the established drug 
transport model to investigate the intravascular drug delivery from a drug-eluting stent 
with biodegradable coating.  
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NOMENCLATURE 
B bound drug concentration 
C free drug concentration 
C0 initial drug concentration in the coating 
Cs drug solubility in the coating 
D1 diffusivity in the stent coating 
D2 isotropic diffusivity in the arterial wall 
D2x transmural diffusivity in the arterial wall 
D2y circumferential diffusivity in the arterial wall 
h mesh size 
K binding equilibrium constant, ka/kd 
ka association rate constant 
kd dissociation rate constant 
R mass transfer resistance 
S available binding sites in the arterial wall 
S0 initial binding sites concentration in the arterial wall 
Greek Symbols  
Δt time step 
κ drug partition coefficient  
τ1 diffusion time scale in the coating 
τ2 diffusion time scale in the arterial wall 
τ3 time scale of drug binding reaction 
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APPENDIX A 
SIMULATION VERIFICATION BY ANALYTICAL 
SOLUTION IN 1–D CASE 
A.1 Introduction 
The verification of the Matlab program code is completed by comparing the simulation 
results to analytical solutions. In order to acquire a feasible analytical solution, high drug 
loading case (continuum pharmacokinetics) is investigated (detail descriptions of high 
drug loading case can be referred to in Chapter 3). A zero value of circumferential 
diffusivity reduces the problem to a one-dimensional (1–D) case.  
A.2 Analytical Solution of Continuum Pharmacokinetics in 1–D  
At high drug loading in the stent coating, the free and bound drug concentrations in the 
arterial wall achieve quasi-equilibrium levels before the drug aggregates are depleted in 
the coating. 
Under quasi-equilibrium state, the drug concentrations in the wall are described 
by a set of ordinary differential equations, Eqs. A (1) and A (2). 
For free drug in the arterial wall,  
2
2 0
d C
dx
=  A (1) 
For bound drug in the arterial wall, 
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0( ) 0a d
dB k C S B k B
dt
= − − =  A (2) 
The boundary conditions at the coating-arterial wall interface and perivascular 
boundary are described in Eqs. A (3) and A (4), respectively. 
SC C=  A (3) 
1 ( )wallperi peri
wp wp
C
J C
R κ= −  A (4) 
Substitute values from Table 1 and solve the ODEs to get the analytical solutions: 
Free drug in the arterial wall 
2
( )S S
per x
C
C x L C
R D L
= − − ++  A (5) 
Bound drug in the arterial wall 
0a
a d
k CS
B
k C k
= +  A (6) 
A.3 Simulation Results Compared With Analytical Solution 
Simulation of the same parameters gives identical results as the analytical solution (Eqs. 
A (5) & A (6), as shown in Figure A1. This confirms the validity of the Matlab code for 
this model. 
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Figure A1. Free and bound drug concentrations in the arterial wall at quasi-equilibrium 
in the test case. Coating-arterial interface starts at x = 240 µm. 
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